Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg and Sonrotoclax With MRD-Guided Addition of Obinutuzumab for Treatment-Naïve CLL or SLL
NCT07887061Phase 2Not yet recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2027
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacabrutideg and sonrotoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Undetectable Measurable Residual Disease at 10^-4 at 56 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
tacabrutidegsonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07887061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887061.